VentriPoint Diagnostics Ltd.VPT - TSX Venture
Shares issued: - 102.6 million
Fully diluted: - 134.0 million
*****************************
VentriPoint announced today that another prestigious institution, the Children’s Hospital and Medical Center in Omaha, Nebraska has joined the clinical trials to validate its VMS™ 3D imaging technology.
This is again adding momentum in advancing the science of VMS™ and overall market awareness.
Even more good news is that Dr. Shelby Kutty who is l
eading the clinical trials in Omaha will be presenting the findings of the study to the EuroEcho Congress in Budapest, next week.
The significant item in the press release is that the FDA has sent a letter and response to the company’s latest submission (July 20, 2011) suggesting clarifications to the clinical trial and plan, which the company is implementing. The key here is that the FDA will be meeting with VentriPoint on January 5, 2012 to review its regulatory submissions for approval of the VMS™ heart analysis system. FDA approval is a significant milestone for the company to have as it will enhance its ability for market penetration dramatically.
The company does believe FDA approval will be forthcoming after this meeting...
